{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:36:49Z","timestamp":1792759009832,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Pegloticase rapidly lowers serum urate in uncontrolled\/refractory gout patients, with \u22651 tophus resolution in 70% of pegloticase responders and 28% of non-responders. Dual-energy computed tomography (DECT) non-invasively detects MSU deposition, including subclinical deposition, quantifies MSU volumes and depicts bone erosions. This report presents DECT findings in MIRROR open-label trial participants receiving pegloticase+MTX co-therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serial DECT scans were obtained during pegloticase (8\u2009mg biweekly infusions)+oral MTX (15\u2009mg\/week) co-therapy. Bilateral hand\/wrist, elbow, foot\/ankle and knee images were analysed with default post-processing settings. MSU volumes were quantified and bone erosions were identified and evaluated for remodelling (decreased size, sclerosis, new bone formation). DECT and physical examination findings were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>2 patients underwent serial DECT. Patient 1 (44-year-old male) completed 52\u00a0weeks of pegloticase+MTX co-therapy (26 infusions). Baseline examination detected 4 tophus-affected joints while DECT identified 73 MSU-affected joints (total MSU volume: 128.76\u2009cm3). At end-of-treatment, there were no clinically-affected joints and 4 joints with DECT-detected MSU deposition. MSU volume decreased by 99% and bone erosion remodelling was evident. Patient 2 (51-year-old male) had 10\u00a0weeks of therapy (5 infusions), discontinuing because of urate-lowering response loss. Baseline examination detected 7 tophus-affected joints while DECT identified 55 MSU-affected joints (total MSU volume: 59.20\u2009cm3). At end-of-treatment, there were 5 clinically affected joints and 42 joints with DECT-detected MSU deposition. MSU volume decreased by 58% and bone erosion remodelling was evident.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>DECT detected subclinical MSU deposition and quantified changes over time. Rapid tophus resolution and bone erosion remodelling occurred during pegloticase+MTX co-therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov, NCT03635957.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keac173","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T04:13:58Z","timestamp":1647404038000},"page":"4898-4904","source":"Crossref","is-referenced-by-count":27,"title":["Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy"],"prefix":"10.1093","volume":"61","author":[{"given":"Nicola","family":"Dalbeth","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Auckland , Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-8504","authenticated-orcid":false,"given":"Fabio","family":"Becce","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Lausanne University Hospital, University of Lausanne , Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"Botson","sequence":"additional","affiliation":[{"name":"Orthopedic Physicians Alaska , Anchorage, Alaska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Medical Affairs, Horizon Therapeutics plc , Deerfield, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Kumar","sequence":"additional","affiliation":[{"name":"Medical Affairs, Horizon Therapeutics plc , Deerfield, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"2022112912431997000_keac173-B1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"2022112912431997000_keac173-B2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13075-018-1782-x","article-title":"Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase","volume":"20","author":"Mandell","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022112912431997000_keac173-B3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","article-title":"2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout","volume":"79","author":"Richette","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022112912431997000_keac173-B4","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/ard.2008.099713","article-title":"Dual energy computed tomography in tophacheous gout","volume":"68","author":"Choi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022112912431997000_keac173-B5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/annrheumdis-2014-206397","article-title":"Urate crystal deposition in asymptomatic hyperuricemia and symptomatic gout: a dual energy CT study","volume":"74","author":"Dalbeth","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022112912431997000_keac173-B6","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/art.40929","article-title":"Effects of allopurinol dose escalation on bone erosion and urate volume in gout: a dual-energy computed tomography imaging study within a randomized, controlled trial","volume":"71","author":"Dalbeth","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022112912431997000_keac173-B7","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/annrheumdis-2013-204273","article-title":"Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study","volume":"74","author":"Dalbeth","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022112912431997000_keac173-B8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/rheumatology\/keq335","article-title":"Development of a computed tomography method of scoring bone erosion in patients with gout: validation and clinical implications","volume":"50","author":"Dalbeth","year":"2011","journal-title":"Rheumatology"},{"key":"2022112912431997000_keac173-B9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3899\/jrheum.200460","article-title":"Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR)","volume":"48","author":"Botson","year":"2021","journal-title":"J Rheumatol"},{"key":"2022112912431997000_keac173-B10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acr.22059","article-title":"Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy","volume":"66","author":"Dalbeth","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2022112912431997000_keac173-B11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2214\/AJR.14.13901","article-title":"Getting the most from your dual-energy scanner: recognizing, reducing, and eliminating artifacts","volume":"206","author":"Coupal","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"2022112912431997000_keac173-B12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40744-019-0151-9","article-title":"Use of pre-infusion serum uric acid levels as a biomarker for infusion reaction risk in patients on pegloticase","volume":"6","author":"Keenan","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2022112912431997000_keac173-B13","doi-asserted-by":"crossref","first-page":"e000075","DOI":"10.1136\/rmdopen-2015-000075","article-title":"Tophus resolution with pegloticase: a prospective dual-energy CT study","volume":"1","author":"Araujo","year":"2015","journal-title":"RMD Open"},{"key":"2022112912431997000_keac173-B14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/RLI.0000000000000756","article-title":"Dual-energy computed tomography for detection and characterization of monosodium urate, calcium phyrophosphate, and hyrdoxyapatite: a phantom study on diagnositc performance","volume":"56","author":"D\u00f8ssing","year":"2021","journal-title":"Invest Radiol"},{"key":"2022112912431997000_keac173-B15","doi-asserted-by":"crossref","first-page":"105178","DOI":"10.1016\/j.jbspin.2021.105178","article-title":"Drastic monosodium urate crystal dissolution with febuxostat and benzbromarone","volume":"88","author":"Pascart","year":"2021","journal-title":"Jt Bone Spine"},{"key":"2022112912431997000_keac173-B16","first-page":"SI81\u20135","article-title":"Two-year reduction of dual-energy CT urate deposition during a treat-to-target strategy in gout in the NOR-Gout longitudinal study","volume":"61(SI","author":"Uhlig","year":"2022","journal-title":"Rheumatology"},{"key":"2022112912431997000_keac173-B17","doi-asserted-by":"crossref","first-page":"R165","DOI":"10.1186\/ar3913","article-title":"Characterization of new bone formation in gout: a quantitative site-by-site analysis using plain radiography and computed tomography","volume":"14","author":"Dalbeth","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2022112912431997000_keac173-B18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/acr2.11172","article-title":"A detailed analysis of the association between urate deposition and erosions and osteophytes in gout","volume":"2","author":"Pecherstorfer","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2022112912431997000_keac173-B19","doi-asserted-by":"crossref","first-page":"e18431","DOI":"10.1097\/MD.0000000000018431","article-title":"Relationship between urate within tophus and bone erosion according to the anatomic location of urate deposition in gout: a quantitative analysis using dual-energy CT volume measurements","volume":"98","author":"Shi","year":"2019","journal-title":"Medicine"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac173\/43682603\/keac173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/12\/4898\/47385892\/keac173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/12\/4898\/47385892\/keac173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T21:54:53Z","timestamp":1700344493000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/12\/4898\/6549522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,3,16]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac173","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,3,16]]}}}